Dr Ribero speaks with ecancer at EADO 2017 about the prognostic and diagnostic value of histologic regression in predicting and tracking immune response to skin cancers.

He notes improved tumour infiltration by patients with regressed melanoma, and considers how this may guide immunotherapy treatments in the future.

Dr Ribero also raises discussion about the role of nevi in regression.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.